Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 21, 2018

Study Completion Date

March 21, 2018

Conditions
Community-acquired Bacterial Pneumonia
Interventions
DRUG

Solithromycin

DRUG

Standard of Care

Age- and weight-based dosing as appropriate per sites standard of care.

Trial Locations (58)

1000

Manila

1083

Budapest

1089

Budapest

1097

Budapest

1100

Quezon City

1104

Quezon City

1125

Budapest

1233

Sofia

1400

Caloocan City

1407

Sofia

1431

Sofia

1781

City of Muntinlupa

2045

Törökbálint

2700

Cegléd

3001

Vratsa

4000

Plovdiv

4031

Debrecen

4400

Nyíregyháza

5000

Iloilo City

5700

Gyula

5800

Pleven

6000

Cebu City

6720

Szeged

7002

Rousse

7257

Mosdós

8000

Székesfehérvár

Davao City

8200

Veszprém

8800

Nagykanizsa

9024

Győr

17033

Hershey

20010

Washington D.C.

20014

Donostia / San Sebastian

22905

Charlottesville

24013

Roanoke

27710

Durham

27834

Greenville

28046

Madrid

29298

Richmond

33606

Tampa

38105

Memphis

40202

Louisville

43606

Toledo

72202

Little Rock

77030

Houston

77372

Splendora

79106

Amarillo

89102

Las Vegas

90095

Los Angeles

92123

San Diego

95817

Sacramento

97239

Portland

68198-2162

Omaha

08950

Esplugues de Llobregat

08035

Barcelona

08916

Barcelona

N18 1QX

London

SW17 0RE

London

Sponsors
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Melinta Therapeutics, Inc.

INDUSTRY